Skip to main content
Premium Trial:

Request an Annual Quote

Latest Sequencer Placement Boosts Helicos Shares

NEW YORK (GenomeWeb News) – Shares of Helicos BioSciences got a double-digit boost today after the company announced that it had placed a Helicos Genetic Analysis System at the Ontario Institute for Cancer Research.

In mid-morning trade on the Nasdaq exchange on Thursday, the company's shares were up 40 percent to $1.40.

The instrument placement was the latest in a string of such agreements that the company has announced in recent weeks, including the sale of an instrument to an undisclosed biotechnology company and another placement at Massachusetts General Cancer Center.

Helicos President Steve Lombardi told GenomeWeb Daily News sister publication In Sequence earlier this week that there are now seven instruments outside of the company, including four placements at research institutes and three ordered by customers.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.